Markets

Antibody-Drug Conjugates (ADCs)

ADCs: Supporting Innovation in Targeted Therapies

The innovative structure of ADCs enables precise delivery to tumor cells while reducing off-target effects.

Most ADCs are lyophilized to preserve linker and payload stability. While IV infusion is common for oncology, alternative routes like subcutaneous delivery are being actively explored.

Extending shelf-life and maintaining drug product stability mainly for liquid formulations, and particularly those light sensitive
Minimizing physical (e.g., fogging effect with lyophilized drugs) and chemical (e.g., corrosion and delamination risk with liquid drugs or diluents) interaction with primary packaging components
Reducing scrap and breakage risks during processing (e.g., lyophilization stress) and use by the healthcare operators due to drug toxicity
Managing small-size batches with minimal waste ensuring flexible manufacturing and cost-efficiency

Stevanato Group as the right partner for ADCs through our integrated offering

Stevanato Group supports the advancement of ADCs with comprehensive solutions across the entire pharmaceutical value chain. From early-stage development to commercial scale-up, our integrated offering helps accelerate time-to-market while ensuring quality and regulatory compliance.